Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- Procedure: Selective Laser TrabeculoplastyProcedure: Sham Selective Laser Trabeculoplasty
- Registration Number
- NCT02507687
- Lead Sponsor
- AbbVie
- Brief Summary
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 240
- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye that require IOP lowering treatment.
- In the investigator's opinion, patient's IOP is not adequately managed with topical medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence).
- In the investigator's opinion, both eyes can be treated adequately with topical prostamide, prostaglandin, or prostaglandin analog eye drops as the sole therapy if medication was taken as directed, or with SLT monotherapy.
- History of previous laser trabeculoplasty
- History or evidence of complicated cataract surgery: eg, surgery resulting in complicated lens placement (such as anterior chamber intraocular lens implant [IOL], sulcus IOL, aphakia, etc) or intraoperative complications (such as a posterior capsular tear [with or without vitreous loss], substantial iris trauma, etc) or history of phakic IOL insertion for refractive error correction
- Intraocular surgery (including cataract surgery) and/or any ocular laser surgery within the 6 months prior to treatment
- Previous use of commercially available Bimatoprost SR; concurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which an implant was received.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye) Sham Bimatoprost SR Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administered on Day 1 followed by up to three sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye) Selective Laser Trabeculoplasty Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administered on Day 1 followed by up to three sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye) Sham Selective Laser Trabeculoplasty Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administered on Day 1 followed by up to three sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Sham Bimatoprost SR Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to three sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Selective Laser Trabeculoplasty Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to three sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Sham Selective Laser Trabeculoplasty Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to three sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye) Sham Bimatoprost SR Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria are met. Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye) Selective Laser Trabeculoplasty Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria are met. Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye) Sham Selective Laser Trabeculoplasty Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria are met. Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye) Sham Bimatoprost SR Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria were met. Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye) Selective Laser Trabeculoplasty Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria were met. Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye) Sham Selective Laser Trabeculoplasty Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria were met. Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye) Bimatoprost SR Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to three sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye) Bimatoprost SR Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administered on Day 1 followed by up to three sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only). Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye) Bimatoprost SR Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Contralateral Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria are met. Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye) Bimatoprost SR Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye: Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations. Contralateral Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations. Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria were met.
- Primary Outcome Measures
Name Time Method Change From Baseline in Intraocular Pressure at Week 4 Baseline and Week 4 Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. A mixed-effects model with repeated measures (MMRM) was used for the analysis. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.
Change From Baseline in Intraocular Pressure at Week 12 Baseline and Week 12 Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. An MMRM was used for the analysis. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.
Change From Baseline in Intraocular Pressure at Week 24 Baseline and Week 24 Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. An MMRM was used for the analysis. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.
- Secondary Outcome Measures
Name Time Method Time to Initial Use of Non-study IOP-lowering Treatment From first administration of study treatment to the end of study; overall median follow-up time of 728 days. The time from the date of initial treatment to the date date of first use of non-study IOP-lowering treatment (rescue) was analyzed using the Kaplan-Meier method.
If a participant did not use any non-study IOP-lowering treatment in an eye, then the event (initial use of non-study IOP-lowering treatment) time was censored at the study exit date or the last visit date if the study exit date was not available.Percentage of Eyes Achieving ≥ 20% Reduction in IOP From Baseline Regardless of Cycle Baseline, Day 2, Weeks 4, 8, 12, 15, 20, 24, 28, 31, 36, 40, 44, 47, 52, Months 13, 14, 15, 16, 18, 20, 22, 24 Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer.
For by-cycle analyses, cycle number refers to the administration cycle for bimatoprost SR, or sham bimatoprost SR administration in SLT-treated eyes. For SLT-treated eyes cycle number does not refer to SLT administrations, because SLT was only performed once (Day 1). The Day/Week number refers to the number of days/weeks after bimatoprost SR/sham bimatoprost SR administration.
IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.Change From Baseline in IOP at Weeks 8, 15, and 20 Baseline and Weeks 8, 15, and 20 IOP was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.
Trial Locations
- Locations (95)
Wolstan & Goldberg Eye Associates /ID# 235166
🇺🇸Torrance, California, United States
Trinity Research Group /ID# 234598
🇺🇸Dothan, Alabama, United States
Houston Eye Associates /ID# 237883
🇺🇸Houston, Texas, United States
Queen Mary's Hospital /ID# 234899
🇬🇧Greater London, Kent, United Kingdom
Arizona Glaucoma Specialists /ID# 235066
🇺🇸Phoenix, Arizona, United States
Pacific Eye Associates /ID# 235326
🇺🇸San Francisco, California, United States
San Antonio Eye Center /ID# 235632
🇺🇸San Antonio, Texas, United States
Medical Center Ophthalmology Associates /ID# 235016
🇺🇸San Antonio, Texas, United States
Speciality Eye Care Medical Group /ID# 236001
🇺🇸Glendale, California, United States
Segal Drug Trials Inc. /ID# 235169
🇺🇸Delray Beach, Florida, United States
Levenson Eye Associates Inc. /ID# 235021
🇺🇸Jacksonville, Florida, United States
Clayton Eye Clinical Research, LLC /ID# 236678
🇺🇸Morrow, Georgia, United States
Eye Care Specialists /ID# 235129
🇺🇸Kingston, Pennsylvania, United States
Baylor College of Medicine - Baylor Medical Center /ID# 237148
🇺🇸Houston, Texas, United States
Albemarle Clinical Trials LLC /ID# 235144
🇺🇸Elizabeth City, North Carolina, United States
Scott and Christie and Associates /ID# 234594
🇺🇸Cranberry Township, Pennsylvania, United States
Emerson Clinical Research Institute /ID# 235977
🇺🇸Falls Church, Virginia, United States
Oklahoma Eye Surgeons /ID# 235848
🇺🇸Oklahoma City, Oklahoma, United States
Eye associates /ID# 236501
🇺🇸San Antonio, Texas, United States
Eye Associates of New Mexico /ID# 235115
🇺🇸Albuquerque, New Mexico, United States
Wills Eye Hospital /ID# 236487
🇺🇸Philadelphia, Pennsylvania, United States
Eye Surgery Associates /ID# 235872
🇦🇺East Melbourne, Victoria, Australia
Rabin Medical Center /ID# 237698
🇮🇱Petakh Tikva, Israel
Southern Eye Specialists /ID# 236081
🇳🇿Christchurch, Canterbury, New Zealand
Polyclinique de la Baie /ID# 235842
🇫🇷Avranches, France
CHU Strasbourg - Hopital Civil /ID# 237837
🇫🇷Strasbourg cedex, France
Chu Angers /Id# 237805
🇫🇷Angers, France
The Lions Eye Institute /ID# 236832
🇦🇺Nedlands, Western Australia, Australia
Geelong Eye Clinic /ID# 236118
🇦🇺Geelong, Australia
Vision Eye Institute /ID# 236003
🇦🇺Melbourne, Australia
Tel Aviv Sourasky Medical Center /ID# 237211
🇮🇱Tel Aviv-Yafo, Tel-Aviv, Israel
Clinique Honore Cave - Pharmacie /ID# 235925
🇫🇷Montauban, France
CHU de Nice - Hospital Pasteur 2 /ID# 235844
🇫🇷Nice, France
Cambridge University Hospitals NHS Foundation Trust /ID# 238315
🇬🇧Cambridge, United Kingdom
Rigshospitalet Glostrup /ID# 237709
🇩🇰Glostrup, Hovedstaden, Denmark
Ophthalmology Clinic Bellevue /ID# 234631
🇨🇦Montreal, Quebec, Canada
Moorfields Eye Hospital NHS Foundation Trust /ID# 237708
🇬🇧London, United Kingdom
NHS Lothian /ID# 237450
🇬🇧Edinburgh, United Kingdom
Imperial College Healthcare NHS Trust /ID# 234777
🇬🇧London, United Kingdom
Manchester University NHS Foundation Trust /ID# 237318
🇬🇧Manchester, United Kingdom
Chu Toulouse Purpan - Hopital Pierre Paul Riquet /ID# 235841
🇫🇷Toulouse, France
Arizona Advanced Eye Research Institute /ID# 234947
🇺🇸Glendale, Arizona, United States
M&M Eye Institute /ID# 235391
🇺🇸Prescott, Arizona, United States
Orange County Ophthalmology /ID# 235995
🇺🇸Garden Grove, California, United States
Lakeside Vision Center /ID# 234971
🇺🇸Irvine, California, United States
Walman Eye Center /ID# 236054
🇺🇸Sun City, Arizona, United States
California Center for Clin Res /ID# 237412
🇺🇸Arcadia, California, United States
Lugene Eye Institute /ID# 237042
🇺🇸Glendale, California, United States
North Bay Eye Associates Inc. /ID# 235429
🇺🇸Petaluma, California, United States
California Eye Specialists Medical Group Inc. /ID# 235999
🇺🇸Pasadena, California, United States
University of Florida /ID# 236876
🇺🇸Jacksonville, Florida, United States
Eye Associates of South West Florida /ID# 235424
🇺🇸Fort Myers, Florida, United States
Ocala Eye PA /ID# 235431
🇺🇸Ocala, Florida, United States
Cincinnati Eye Institute- Edgewood /ID# 236714
🇺🇸Edgewood, Kentucky, United States
University of Illinois at Chicago Illinois Eye and Ear Infirmary /ID# 234875
🇺🇸Chicago, Illinois, United States
Sabates Eye Centers /ID# 234868
🇺🇸Leawood, Kansas, United States
Advanced Glaucoma Specialists /ID# 234799
🇺🇸Reading, Massachusetts, United States
Fraser Eye Center /ID# 235791
🇺🇸Fraser, Michigan, United States
Northern New Jersey Eye Institute PA /ID# 234944
🇺🇸South Orange, New Jersey, United States
Bagan Strinden Vision /ID# 234898
🇺🇸Fargo, North Dakota, United States
Midwest Vision Research Foundation at Pepose Vision Institute /ID# 235879
🇺🇸Chesterfield, Missouri, United States
Family Eye Group P.C. /ID# 236114
🇺🇸Lancaster, Pennsylvania, United States
Chattanooga Eye Institute /ID# 235250
🇺🇸Chattanooga, Tennessee, United States
Piedmont Eye Center /ID# 234533
🇺🇸Lynchburg, Virginia, United States
West Virginia University Eye Institute /ID# 235174
🇺🇸Morgantown, West Virginia, United States
Melbourne Eye Specialists /ID# 234614
🇦🇺Fitzroy, Victoria, Australia
Waverley Eye Clinic /ID# 234997
🇦🇺Glen Waverley, Victoria, Australia
Essendon Eye Clinic /ID# 235433
🇦🇺Essendon, Australia
CHU Bordeaux - Hopital Pellegrin /ID# 237705
🇫🇷Bordeaux, France
Internationale Innovative Ophthalmochirurgie /ID# 235263
🇩🇪Dusseldorf, Nordrhein-Westfalen, Germany
Universitaetsklinikum Magdeburg /ID# 237284
🇩🇪Magdeburg, Germany
Rambam Health Care Campus /ID# 237741
🇮🇱Haifa, Israel
Capital Eye Specialists /ID# 236111
🇳🇿Wellington, New Zealand
Galilee Medical Center /ID# 235742
🇮🇱Nahariya, Israel
Auckland Eye Hospital /ID# 235253
🇳🇿Remuera, Auckland, New Zealand
Peregrine Eye and Laser Institute /ID# 236220
🇵🇭Makati City, Philippines
American Eye Center /ID# 235320
🇵🇭Makati City, Philippines
Asian Eye Institute /ID# 235092
🇵🇭Makati City, Philippines
Cardinal Santos Medical Center /ID# 235325
🇵🇭San Juan City, Philippines
Clinical ophthalmology hospital n.a. V.P. Vihodtsev. /ID# 236041
🇷🇺Omsk, Russian Federation
Samara State Medical University /ID# 236997
🇷🇺Samara, Russian Federation
Guys and St Thomas NHS Foundation Trust /ID# 236806
🇬🇧London, London, City Of, United Kingdom
University Hospital of Derby and Burton NHS Foundation Trust /ID# 237129
🇬🇧Derby, Derbyshire, United Kingdom
Epsom & St Helier University Hospital NHS Trust /ID# 236902
🇬🇧Carshalton, Surrey, United Kingdom
Duplicate_Cornerstone Eye Care /ID# 235047
🇺🇸High Point, North Carolina, United States
Carolinas Centers for Sight,PC /ID# 237017
🇺🇸Florence, South Carolina, United States
Cross Eye Center /ID# 236116
🇺🇸Bellaire, Texas, United States
Queensland Eye Institute /ID# 236074
🇦🇺South Brisbane, Queensland, Australia
The Lady Davis Carmel Medical Center /ID# 236757
🇮🇱Haifa, Israel
Dr. Andrew Gardner Logan, FL /ID# 236946
🇺🇸Tamarac, Florida, United States
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 235966
🇩🇪Berlin, Germany
Centrum Diagnostyki i Mikrochirurgii Oka - LENS dr n. med. Slawomir Zalewski /ID# 235929
🇵🇱Olsztyn, Poland
University of South Florida /ID# 237737
🇺🇸Tampa, Florida, United States
The Eye Care Institute /ID# 236690
🇺🇸Louisville, Kentucky, United States
ATX Clinical Trials Inc. dba Keystone Research /ID# 235869
🇺🇸Austin, Texas, United States